Published: 19 February 2024
Author(s): Steven A Muller, Hugh Calkins, Alessio Gasperetti
Issue: May 2024
Section: Commentary

Cardiac amyloidosis (CA) is a progressive and life-threatening cardiomyopathy characterized by deposition of misfolded proteins in the myocardium, leading to heart failure (HF), conduction disorders, and (supra)ventricular arrhythmias. Disease prognosis is mainly determined by (a) the presence of HF at time of diagnosis and (b) etiology of the misfolded proteins (i.e. light chain (AL) or transthyretin [TTR] amyloidosis [ATTR]), with a median survival of ˜3.5 years, if left untreated [1]. Due to a lack of treatment options in the past, CA was considered untreatable resulting often in underdiagnosis of the disease [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.